# EDGAR Filing Document

**Accession Number:** 0002080252
**File Stem:** 0001213900-25-093045
**Filing Date:** 2025-9
**Character Count:** 16697
**Document Hash:** 9afa219b02ea3a7b656aec65d737ee62
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-093045.hdr.sgml**: 20250929

**ACCESSION NUMBER**: 0001213900-25-093045

**CONFORMED SUBMISSION TYPE**: 3/A

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250620

**FILED AS OF DATE**: 20250929

**DATE AS OF CHANGE**: 20250929

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Ren Jinsheng
- **CENTRAL INDEX KEY:** 0001455397

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38905
- **FILM NUMBER:** 251355968

**MAIL ADDRESS:**
- **STREET 1:** NO. 699-18 XUAN WU AVENUE
- **STREET 2:** XUAN WU DISTRICT
- **CITY:** NANJING
- **STATE:** F4
- **ZIP:** 210042
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.
- **CENTRAL INDEX KEY:** 0002082506

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** F4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38905
- **FILM NUMBER:** 251355971

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** BUILDING 23, NO.699-18, XUANWU AVENUE
- **CITY:** NANJING
- **NON US STATE TERRITORY:** JIANGSU
- **PROVINCE COUNTRY:** F4
- **ZIP:** 00000
- **BUSINESS PHONE:** 86 13472406362

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** BUILDING 23, NO.699-18, XUANWU AVENUE
- **CITY:** NANJING
- **NON US STATE TERRITORY:** JIANGSU
- **PROVINCE COUNTRY:** F4
- **ZIP:** 00000
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Simcere Zaiming, Inc.
- **CENTRAL INDEX KEY:** 0002080252

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38905
- **FILM NUMBER:** 251355972

**BUSINESS ADDRESS:**
- **STREET 1:** 20 ACORN PARK DR, CAMBRIDGE, MA 02140
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02140
- **BUSINESS PHONE:** 15049574163

**MAIL ADDRESS:**
- **STREET 1:** 20 ACORN PARK DR, CAMBRIDGE, MA 02140
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02140
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Tang Renhong
- **CENTRAL INDEX KEY:** 0002088593

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38905
- **FILM NUMBER:** 251355967

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** BUILDING 23, NO.699-18, XUANWU AVENUE
- **CITY:** NANJING
- **NON US STATE TERRITORY:** JIANGSU
- **PROVINCE COUNTRY:** F4
- **ZIP:** 00000
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Simcere Pharmaceutical Group Ltd
- **CENTRAL INDEX KEY:** 0002082516

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** K3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38905
- **FILM NUMBER:** 251355969

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** BUILDING 18, 512 HAIYANG WEST ROAD
- **CITY:** SHANGHAI
- **NON US STATE TERRITORY:** SHANGHAI
- **PROVINCE COUNTRY:** F4
- **ZIP:** 00000
- **BUSINESS PHONE:** 86 15321531998

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** BUILDING 18, 512 HAIYANG WEST ROAD
- **CITY:** SHANGHAI
- **NON US STATE TERRITORY:** SHANGHAI
- **PROVINCE COUNTRY:** F4
- **ZIP:** 00000
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Hainan Simcere Zaiming Pharmaceutical Co., Ltd.
- **CENTRAL INDEX KEY:** 0002088064

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** F4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38905
- **FILM NUMBER:** 251355970

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** NO 20, YAOGUYIHENG ROAD
- **STREET 2:** XIUYING DISTRICT
- **CITY:** HAIKOU
- **NON US STATE TERRITORY:** HAINAN
- **PROVINCE COUNTRY:** F4
- **ZIP:** 00000
- **BUSINESS PHONE:** 86 13472406362

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** NO 20, YAOGUYIHENG ROAD
- **STREET 2:** XIUYING DISTRICT
- **CITY:** HAIKOU
- **NON US STATE TERRITORY:** HAINAN
- **PROVINCE COUNTRY:** F4
- **ZIP:** 00000
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NextCure, Inc.
- **CENTRAL INDEX KEY:** 0001661059
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 475231247
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 9000 VIRGINIA MANOR ROAD, SUITE 200
- **CITY:** BELTSVILLE
- **STATE:** MD
- **ZIP:** 20705
- **BUSINESS PHONE:** 240-399-4900

**MAIL ADDRESS:**
- **STREET 1:** 9000 VIRGINIA MANOR ROAD, SUITE 200
- **CITY:** BELTSVILLE
- **STATE:** MD
- **ZIP:** 20705

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3/A

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Simcere Zaiming, Inc.<br><sub>(Last) (First) (Middle)</sub><br>20 ACORN PARK DR.<br><sub>(Street)</sub><br>CAMBRIDGE, MA 02140<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-06-20 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>NextCure, Inc. [ NXTC ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.<br><sub>(Last) (First) (Middle)</sub><br>BUILDING 23, NO.699-18,<br>XUANWU AVENUE, NANJING<br><sub>(Street)</sub><br>NANJING CITY, JIANGSU PROVINCE, F4 210000<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-06-20 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>NextCure, Inc. [ NXTC ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Hainan Simcere Zaiming Pharmaceutical Co., Ltd.<br><sub>(Last) (First) (Middle)</sub><br>NO 20, YAOGUYIHENG ROAD,<br>XIUYING DISTRICT<br><sub>(Street)</sub><br>HAIKOU CITY, HAINAN PROVINCE, F4 570100<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-06-20 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>NextCure, Inc. [ NXTC ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Simcere Pharmaceutical Group Ltd<br><sub>(Last) (First) (Middle)</sub><br>BUILDING 23, NO.699-18,<br>XUANWU AVENUE<br><sub>(Street)</sub><br>NANJING CITY, JIANGSU PROVINCE, F4 210000<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-06-20 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>NextCure, Inc. [ NXTC ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Ren Jinsheng<br><sub>(Last) (First) (Middle)</sub><br>BUILDING 23, NO.699-18,<br>XUANWU AVENUE<br><sub>(Street)</sub><br>NANJING CITY, JIANGSU PROVINCE, F4 210000<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-06-20 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>NextCure, Inc. [ NXTC ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Tang Renhong<br><sub>(Last) (First) (Middle)</sub><br>BUILDING 23, NO.699-18,<br>XUANWU AVENUE<br><sub>(Street)</sub><br>NANJING CITY, JIANGSU PROVINCE, F4 210000<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-06-20 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>NextCure, Inc. [ NXTC ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock |  |  |  |  |  |  |  | 338636 | I | See footnotes<sup>(1)(2)(3)(4)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) These securities are directly held by Simcere Zaiming, Inc. ("Simcere Zaiming") and may be deemed to be indirectly beneficially owned by the other reporting persons (the "Reporting Persons").

(2) Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. ("Jiangsu Zaiming") is the sole shareholder of Simcere Zaiming, Inc. Hainan Simcere Zaiming Pharmaceutical Co., Ltd. ("Hainan Zaiming") is the sole shareholder of Jiangsu Zaiming. Simcere Pharmaceutical Group Limited ("Simcere Group") is the controlling shareholder of Hainan Zaiming through several intermediate companies. Mr. Ren Jinsheng is the chief executive officer and chairman of the board of directors of Simcere Group and a director of Hainan Zaiming. Mr. Tang Renhong is a director of Simcere Group, the chief executive officer and chairman of the board of directors of Hainan Zaiming, a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming. Messrs. Ren Jinsheng and Tang Renhong may be deemed to be the beneficial owners having shared voting power and shared investment power over the securities described in this footnote.

(3) The Reporting Persons disclaim beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that any Reporting Person is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

(4) This amendment is being made solely for the purpose of including Jiangsu Zaiming, Hainan Zaiming, Simcere Group, Mr. Ren Jinsheng and Mr. Tang Renhong as additional reporting persons to the Form 3 filed by Simcere Zaiming on 8/19/2025 (the "Original Form"). Although Jiangsu Zaiming, Hainan Zaiming, Simcere Group, Mr. Ren Jinsheng and Mr. Tang Renhong were disclosed in the Original Form, they were unable to be included as reporting persons because they did not have codes for, or lost electronic access to, the EDGAR system at the time. Other than including Jiangsu Zaiming, Hainan Zaiming, Simcere Group, Mr. Ren Jinsheng and Mr. Tang Renhong as additional reporting persons, this form contains no amendment to the Original Form.

**Remarks:**
Exhibit List: Exhibit 24 - Power of Attorney, incorporated by reference to Exhibit 24 to the Schedule 13G filed by Reporting Persons with the Securities and Exchange Commission on August 19, 2025

**Signature:** Simcere Zaiming, Inc. By: /s/ Renhong Tang, Chief Executive Officer  
**Date:** 2025-09-29

**Signature:** Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. By: /s/ Renhong Tang Director and Attorney-in-Fact  
**Date:** 2025-09-29

**Signature:** Hainan Simcere Zaiming Pharmaceutical Co., Ltd. By: /s/ Renhong Tang Chief Executive Officer and Chairman of the Board of Directors  
**Date:** 2025-09-29

**Signature:** Simcere Pharmaceutical Group Limited By: /s/ Jinsheng Ren Chief Executive Officer and Chairman of the Board of Directors  
**Date:** 2025-09-29

**Signature:** Jinsheng Ren By: /s/ Jinsheng Ren  
**Date:** 2025-09-29

**Signature:** Renhong Tang By: /s/ Renhong Tang  
**Date:** 2025-09-29

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**